New hope for advanced breast cancer: experimental drug targets resistant tumors

NCT ID NCT03624543

First seen Jan 30, 2026 · Last updated May 04, 2026 · Updated 14 times

Summary

This study tests an experimental drug called CFI-400945 in people with advanced or metastatic breast cancer that has not responded to standard chemotherapy. The goal is to see if the drug can shrink tumors or control the disease. About 51 participants will receive the drug, and researchers will monitor tumor response and side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Allan Blair Cancer Centre

    Regina, Saskatchewan, S4T 7T1, Canada

  • Juravinski Cancer Centre at Hamilton Health Sciences

    Hamilton, Ontario, L8V 5C2, Canada

  • London Regional Cancer Program

    London, Ontario, N6A 5W9, Canada

  • Odette Cancer Centre

    Toronto, Ontario, M4N 3M5, Canada

  • Ottawa Hospital Research Institute

    Ottawa, Ontario, K1H 8L6, Canada

  • University Health Network

    Toronto, Ontario, M5G 2M9, Canada

Conditions

Explore the condition pages connected to this study.